Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort.
antipsychotic
clustering
first-episode
personalized medicine
predictive factors
psychosis
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
30
05
2019
revised:
16
09
2019
accepted:
17
11
2019
pubmed:
21
11
2019
medline:
10
7
2021
entrez:
21
11
2019
Statut:
ppublish
Résumé
Here, we present a clustering strategy to identify phenotypes of antipsychotic (AP) response by using longitudinal data from patients presenting first-episode psychosis (FEP). One hundred and ninety FEP with complete data were selected from the PEPs project. The efficacy was assessed using total PANSS, and adverse effects using total UKU, during one-year follow-up. We used the Klm3D method to cluster longitudinal data. We identified four clusters: cluster A, drug not toxic and beneficial; cluster B, drug beneficial but toxic; cluster C, drug neither toxic nor beneficial; and cluster D, drug toxic and not beneficial. These groups significantly differ in baseline demographics, clinical, and neuropsychological characteristics (PAS, total PANSS, DUP, insight, pIQ, age of onset, cocaine use and family history of mental illness). The results presented here allow the identification of phenotypes of AP response that differ in well-known simple and classic clinical variables opening the door to clinical prediction and application of personalized medicine.
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-552Investigateurs
Amalia Lafuente
(A)
Miquel Bioque
(M)
Covadonga M Diaz-Caneja
(CM)
Javier González-Peñas
(J)
Anna Alonso Solis
(AA)
Mireia Rebella
(M)
Itxaso González-Ortega
(I)
Ariadna Besga
(A)
Julio SanJuan
(J)
Juan Nacher
(J)
Laura Morro
(L)
Clara Montserrat
(C)
Esther Jimenez
(E)
Susana Gomes Da Costa
(SGD)
Immaculada Baeza
(I)
Elena de la Serna
(E)
S Rivas
(S)
C Diaz
(C)
Pilar A Saiz
(PA)
Leticia Garcia-Álvarez
(L)
Miguel Gutierrez Fraile
(MG)
Arantzazu Zabala Rabadán
(AZ)
Iosune Torio
(I)
Roberto Rodríguez-Jimenez
(R)
Anna Butjosa
(A)
Marta Pardo
(M)
Salvador Sarró
(S)
Edith Pomarol-Clotet
(E)
Angela Ibañez Cuadrado
(AI)
Manuel J Cuesta
(MJ)
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Fond G, d'Albis MA, Jamain S et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull 2015;41:559-573.
Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.
Zhang JP, Malhotra AK. Recent progress in pharmacogenomics of antipsychotic drug response. Curr Psychiatry Rep 2018;20:24.
Zai CC, Tiwari AK, Zai GC, Maes MS, Kennedy JL. New findings in pharmacogenetics of schizophrenia. Curr Opin Psychiatry 2018;31:200-212.
Serretti A. The present and future of precision medicine in psychiatry: focus on clinical psychopharmacology of antidepressants. Clin Psychopharmacol Neurosci 2018;16:1-6.
Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging 2018;3:223-230.
Lee BS, McIntyre RS, Gentle JE et al. A computational algorithm for personalized medicine in schizophrenia. Schizophr Res 2018;192:131-136.
Cao B, Cho RY, Chen D et al. Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity. Mol Psychiatry 2018; https://doi.org/10.1038/s41380-018-0106-5.
Mas S, Llerena A, Saíz J, Bernardo M, Lafuente A. Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 2012;13:1773-1782.
Hui CLM, Honer WG, Lee EHM et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 2018;5:432-442.
Bernardo M, Bioque M. What have we learned from research into first-episode psychosis? Rev Psiquiatr Salud Ment (Barc) 2014;7(2):61-63.
Kahn RS, Fleischhacker WW, Boter H et al. EUFEST study group Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097.
National Institute of Health and Care Excellence. Medicines optimization: the safe and effective use of medicines to enable the best possible outcomes. NG 5. 2015. Retrieved from http://nice.org.uk. 18 May 2016
Keating D, McWilliams S, Schneider I et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open 2017;7:e013881.
Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
Bernardo M, Bioque M, Parellada M et al. Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Rev Psiquiatr Salud Ment (Barc) 2013;6:4-16.
Cuesta MJ, Sánchez-Torres AM, Cabrera B et al. Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophr Res 2015;164:65-73.
Pina-Camacho L, Del Rey-Mejías Á, Janssen J et al. Age at first episode modulates diagnosis-related structural brain abnormalities in psychosis. Schizophr Bull 2016;42:344-357.
Bioque M, Llerena A, Cabrera B et al. A pharmacovigilance study in first episode of psychosis: psychopharmacological interventions and safety profiles in the PEPs project. Int J Neuropsychopharmacol 2016;19:pyv121.
Bernardo M, Bioque M, Cabrera B et al. Modelling gene-environment interaction in first episodes of psychosis. Schizophr Res 2017;189:181-189.
Mezquida G, Cabrera B, Bioque M et al. The course of negative symptoms in first-episode schizophrenia and its predictors: a prospective two-year follow-up study. Schizophr Res 2017;189:84-90.
Peralta V, Cuesta MJ. Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso Esp Neurol Psiquiatr 1994;22:171-177.
Parellada M, Fraguas D, Bombín I et al. Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. Psychol Med 2009;39:1433-1445.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
Gassó P, Mas S, Bioque M et al. Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. J Psychopharmacol 2018;32:702-710.
Mas S, Gassó P, Lafuente A et al. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J 2016;16:439-445.
Bioque M, García-Portilla MAP, García-Rizo C et al. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophr Res 2018;193:188-196.
McCutcheon R, Beck K, D'Ambrosio E et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 2018;137:39-46.
Mas S, Gassó P, Torra M et al. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. Eur Neuropsychopharmacol 2017;27:647-656.
Genolini C, Pingault JB, Driss T et al. KmL3D: a non-parametric algorithm for clustering joint trajectories. Comput Methods Programs Biomed 2013;109:104-111.
Ciarrochi J, Sahdra BK, Hawley PH, Devine EK. The upsides and downsides of the dark side: a longitudinal study into the role of prosocial and antisocial strategies in close friendship formation. Front Psychol 2019;10:114.
Hicks JK, McLeod HL. Pharmacogenetics and pharmacogenomics in genomic and precision medicine, 3rd edn (David SP ed). London: Academic Press, 2017:89-107.
Crespo-Facorro B, Pelayo-Teran JM, Mayoral-van Son J. Current data on and clinical insights into the treatment of first episode nonaffective psychosis: a comprehensive review. Neurol Ther 2016;5:105-130.
Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry 1998;172:53-59.
Abdel-Baki A, Ouellet-Plamondon C, Malla A. Pharmacotherapy challenges in patients with first-episode psychosis. J Affect Disord 2012;138:S3-S14.
Cuesta MJ, Peralta V, Campos MS, Garcia-Jalon E. Can insight be predicted in first-episode psychosis patients? A longitudinal and hierarchical analysis of predictors in a drug-naïve sample. Schizophr Res 2011;130:148-156.
Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014;16:505-524.
Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 2007;21(2):129-141.
Sánchez-Torres AM, Zarzuela A, Peralta V, Cuesta MJ. The association of lifetime insight and cognition in psychosis. Schizophr Res 2015;162:183-188.
Sipos A, Harrison G, Gunnell D, Amin S, Singh SP. Patterns and predictors of hospitalisation in first-episode psychosis. Prospective cohort study. Br J Psychiatry 2001;178:518-523.
Mutsatsa SH, Joyce EM, Hutton SB, Barnes TR. Relationship between insight, cognitive function, social function and symptomatology in schizophrenia: the West London first episode study. Eur Arch Psychiatry Clin Neurosci 2006;256:356-363.
Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry 2006;189:31-35.
Crespo-Facorro B, de la Foz VO, Ayesa-Arriola R et al. Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study. Prog Neuropsychopharmacol Biol Psychiatry 2013;44:162-167.
Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-113.
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013;70:913-920.
Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012;138:29-34.
Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci 2013;67:367-383.
Allott K, Liu P, Proffitt TM, Killackey E. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophr Res 2011;125:221-235.
Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. J Clin Psychiatry 2015;76:1535-1545.
Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-136.
Zhu Y, Krause M, Huhn M et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017;4:694-705.
Krause M, Zhu Y, Huhn M et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018; https://doi.org/10.1007/s00406-018-0869-3.
Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry 2017;74:675-684.
Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012;11:527-542.
Parellada E, Velligan DI, Emsley R, Kissling W. Long-acting injectable antipsychotics in first-episode schizophrenia. Schizophr Res Treatment 2012;2012:318535.